ICER’s Protocol on Unsupported Price Increases Discusses 250 Drugs

May 4, 2021

The Institute for Clinical and Economic Review (ICER) recently published a protocol detailing how it determines unjustified price increases. The protocol discusses 250 drugs and focuses on key factors leading to high drug prices, including rebates. ICER is taking suggestions from the public regarding additional drugs associated with unsupported price increases until May 10th.

“The Institute for Clinical and Economic Review has published [a] protocol for its annual “Unsupported Price Increases” report. Some changes include clarification of the submission process and information required of drug makers, expansion of the initial list to 250 drugs, and the CPI threshold. ICER, which has been publishing the UPI report since 2019, proposes to generate a final list of up to 13 prescription drugs with substantial price increases between 2019 and 2020.” Read more here.

(Source: Gabrielle Wanneh, Inside Health Policy, 4/21/21)

Share This Story!